GB 70041
Alternative Names: GB-70041Latest Information Update: 26 Apr 2022
Price :
$50 *
At a glance
- Originator Shanghai Genechem
- Developer Shanghai Genbase Biotechnology; Shanghai Genechem
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Gastric cancer
Most Recent Events
- 21 Apr 2022 GB 70041 is available for licensing as of 21 Apr 2022. www.gcbio.com
- 01 Apr 2022 Preclinical trials in Gastric cancer in China (Parenteral) before April 2022 (Shanghai Genechem pipeline, April 2022) (Shanghai Genbase Biotechnology pipeline, April 2022)